Is Crizotinib on the market?

Crizotinib (Crizotinib) is a tyrosine kinase receptor inhibitor indicated for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, and span>ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT), was approved by the U.S. Food and Drug Administration (FDA) in 2011, and its use is accompanied by an FDA-approved test to detect ALK and ROS1 rearrangements, sold under the trade name Xalkori.

By targeting the echinoderm microtubule-associated protein-like4 (EML4)-ALK fusion protein, crizotinib has strong efficacy in the treatment of non-small cell lung cancer in patients with this rearrangement. In October 2012, the European Medicines Agency (EMA) approved the use of crizotinib to treat non-small cell lung cancer that expresses the abnormal anaplastic lymphoma kinase (ALK) gene. Crizotinib has also been approved for marketing in China through the regulations of the National Medical Products Administration, sold under the trade name of Xalkori, and then included in the scope of medical insurance, but only patients who meet the indications can be reimbursed.

The price of each box of the original crizotinib sold domestically may be around 15,000 yuan; the price of the original Turkish version of crizotinib sold overseas may be more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is expensive. There are also cheaper generic crizotinib drugs available overseas. The ingredients are basically similar to those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Bangladesh pharmaceutical factory may be more than 2,000 yuan per box (the price may fluctuate due to exchange rates).